# U.S. Food and Drug Administration (FDA)

Type: regulator

Source: Legal & RegTech Intelligence Brief — https://getlegalbrief.com/entity/us-food-and-drug-administration-fda-regulator
Canonical HTML page: https://getlegalbrief.com/entity/us-food-and-drug-administration-fda-regulator

## Timeline

- **2026-Q3**: Comment Period Close — Expected deadline for industry stakeholders to submit feedback on the proposed framework.
- **2026-02-24**: Customized Drug Proposal — FDA formally proposes the new system for approving bespoke therapies for rare diseases.
- **2024-03-26**: SCOTUS Mifepristone Hearing — Supreme Court hears arguments regarding the FDA's regulation of medication abortion pills.
- **2024-03-23**: National Data Release — Reports confirm U.S. abortion numbers held steady despite 14 state-level bans.
- **2023-01-01**: Shield Law Expansion — States like MA and NY implement laws protecting providers from out-of-state legal actions.
- **2022-12**: FDORA Enacted — The Food and Drug Omnibus Reform Act authorizes the FDA to establish a Platform Technology Designation.
- **2022-06-24**: Dobbs Decision — U.S. Supreme Court overturns Roe v. Wade, returning abortion regulation to the states.
- **1983**: Orphan Drug Act — Congress passes legislation providing financial incentives for rare disease research.

## Recent coverage (2 stories)

### U.S. Abortion Rates Stabilize Amid Regulatory Fragmentation and Shield Laws
2026-03-24 07:41:40 · Sentiment: Neutral · Impact: 7/10 · Sources: 10

Despite the implementation of near-total bans in 14 states, the national volume of abortions in the U.S. has remained steady or increased. This resilience is driven by a surge in medication abortion, the expansion of telehealth, and the emergence of state 'shield laws' that protect providers across jurisdictional lines.
Full story: https://getlegalbrief.com/story/us-abortion-rates-stability-regulation-shield-laws

### FDA Unveils Regulatory Framework for Bespoke Rare Disease Therapies
2026-02-24 03:15:59 · Sentiment: Bullish · Impact: 8/10 · Sources: 2

The FDA has proposed a landmark regulatory system designed to accelerate the approval of customized, 'bespoke' medicines for ultra-rare diseases. The framework allows manufacturers to leverage data from established platform technologies to streamline the development of individualized genomic treatments.
Full story: https://getlegalbrief.com/story/fda-bespoke-drug-approval-framework

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getlegalbrief.com/guides/methodology for the full editorial methodology.